HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Edgewell Cuts $310m Billie Deal Without FTC Incident

Executive Summary

Acquisition of value-tier, female-first razor firm Billie, Inc. – previously attempted by P&G before the US Federal Trade Commission intervened – will add a youthful, on-message brand to the Schick owner’s women’s shave portfolio. The deal follows Edgewell’s bid to acquire Harry’s in 2020, also thwarted by the FTC.

You may also be interested in...



Unilever Plan To Grow Consumer Health By Acquisition, Meet US Tightening Of Merger Scrutiny

Unilever, which has had three offers for GSK rebuffed, likely notes that the Federal Trade Commission and Department of Justice signal they will tighten scrutiny of deals that merge companies providing consumer-facing products and services.

Alleged ‘Pink Tax’ Class Actions Against OTC Personal-Care Brands Moving Through Federal Courts

Walgreen Co. seeks to dismiss allegations in California’s Northern District that it unlawfully charges more for its OTC Hair Regrowth Treatment for women compared with a “functionally equivalent” offering for men. The suit follows “pink tax” litigation concerning Dove antiperspirants that defendants dismissed in July 2020, a decision affirmed by the Eighth Circuit in May.

P&G Abandons Billie Acquisition; Coty Board Changes; Beauty News In Brief

P&G and women’s razor competitor Billie call off their proposed combination after the FTC made initial moves in December to prevent the deal, deeming it not in consumers’ interest. More cosmetics industry news in brief.

Related Content

Topics

UsernamePublicRestriction

Register

RS151994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel